• Inclusion criteria: ≥1 PsA diagnosis 12 months before or at the date of first biologic use, ≥1 pharmacy claim for ETA, ADA, CER, GOL, or UST from January 1, 2011 to December 31, 2013 (identification period), continuous enrollment and prescription drug benefit for 12 months before and 15 months after first biologic use (index event) in the identification period, and continuous treatment with at least one index biologic in the 3-month look forward period to qualify patients for continuous treatment
• Exclusion criteria: <18 years of age, switched to a different biologic (including infliximab) following the use of their index biologic from index event to end of look-forward period, and any of the following diseases (e.g., Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Juvenile Idiopathic Arthritis, Ulcerative Colitis, Uveitis to confirm that the treatment with the biologic is for the patient's PsA, human immunodeficiency virus, cancer, and tuberculosis to assure that drug was not discontinued due to comorbidity) Outcomes & Analyses
• Clinically meaningful above-label use was defined as a maintenance dose ≥10% higher than indicated in the label for >6 months during the 12-month follow-up period Elixhauser comorbidity score, mean (SD)
PsA-related comorbidity, n (%) • Baseline demographics were similar across treatment groups. The majority of patients were males, with a mean age of ~50 years of age
• PSA-related comorbidities were common, with rates of 75% in the ETA cohort, 77% in the ADA cohort, and 70% in the GOL cohort ( Table 1) RESULTS (Continued) 
Number of days above-label use, mean (SD)
279 (57) 292 (55) 341 (29) ETA, etanercept; ADA, adalimumab; GOL, golimumab; n, number; %, percentage; PsA, Psoriatic Arthritis; SD, standard deviation.
Excess Daily Costs (USD)
• The findings from the above-label use translate into excess daily costs per patient of $77 (ETA), $67 (ADA), and $44 (GOL) (Figure 1) • 
CONCLUSIONS
• This retrospective observational study of real-world dosing from a large US claims database reported that moderate-to-severe PsA patients treated with ETA, ADA, and GOL have above-label use, translating to excess cost of biologics to payers when compared with on-label use
• The frequency of dose escalation may suggest an inadequacy of standard dosing regimens for PSA populations with a high proportion of PsA-related comorbidities 
